PCOS Officially Renamed PMOS: Global Consensus Boosts Diagnosis & Care for 170M Women

A global consensus has officially rebranded polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS), marking a landmark shift in how the condition—affecting an estimated 170 million people worldwide—is understood, diagnosed, and treated. The name change, announced on May 12, 2026, was led by more than 50 patient and professional organizations, including the Endocrine Society, to address long-standing misconceptions about the disorder and improve clinical recognition.

The new name reflects the reality that PMOS is not primarily a condition of ovarian cysts, as its former moniker suggested, but a complex, multisystem endocrine disorder with far-reaching metabolic, reproductive, and mental health impacts. The change aims to reduce stigma, enhance early diagnosis, and accelerate research into its underlying mechanisms and potential treatments.

Why the Name Change?

The term “polycystic ovary syndrome” has been widely criticized for decades as misleading. While the condition often involves small follicular cysts on the ovaries due to irregular ovulation, these cysts are not the core issue. Instead, PMOS is characterized by hormonal imbalances—particularly elevated androgens—that disrupt metabolism, weight regulation, skin health, and mental well-being, alongside reproductive challenges like infertility and irregular periods.

“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,” said Professor Helena Teede, Director of Monash University’s Monash Centre for Health Research & Implementation and an endocrinologist at Monash Health. “It was heart-breaking to see the delayed diagnosis, limited awareness, and inadequate care afforded those affected by this neglected condition.”

“While international guidelines have advanced awareness and care, a name change was the next critical step towards recognition and improvement in the long-term impacts of this condition.”

— Professor Helena Teede, Endocrine Society member

The renaming process, which took years to finalize, was driven by evidence showing that PMOS affects not only reproductive health but also increases risks for obesity, type 2 diabetes, hypertension, depression, and eating disorders. The condition’s systemic nature—spanning endocrine, metabolic, and psychological domains—justified a broader, more accurate descriptor.

A Condition Beyond the Ovaries

PMOS’s expanded name acknowledges that the disorder is not confined to the ovaries or even to people with ovaries. Emerging research suggests it may also affect individuals assigned male at birth, though its presentation and prevalence in these groups remain understudied. The syndrome’s metabolic and endocrine disruptions—such as insulin resistance, dyslipidemia, and chronic inflammation—often go unrecognized until complications arise, delaying interventions that could mitigate long-term risks.

Current treatments for PMOS focus on managing symptoms, such as hormonal therapies to regulate cycles, metformin for insulin resistance, and lifestyle modifications for weight and metabolic health. However, no U.S. Food and Drug Administration–approved therapeutic specifically targets PMOS’s root causes. Advocates hope the new name will spur greater investment in genetic research, biomarker discovery, and precision therapies.

Global Impact and Next Steps

The renaming effort involved collaboration among endocrinologists, gynecologists, primary care physicians, patient advocacy groups, and public health organizations. While the term “PCOS” remains widely recognized in clinical and public discourse, the shift to PMOS is intended to align medical education, diagnostic criteria, and research funding with the condition’s true complexity.

Challenges remain, however. Many healthcare providers may continue to associate the condition with its outdated name, and insurance systems or electronic health records may not yet reflect the change. Patient education campaigns and updates to clinical guidelines will be critical in ensuring the transition improves care rather than creates confusion.

For individuals living with PMOS, the name change symbolizes more than semantics—it represents a long-overdue acknowledgment of their multifaceted health needs. As Professor Teede noted, “This is about more than just a new label. It’s about finally giving voice to the millions who have been misunderstood, misdiagnosed, or left without adequate support.”

With the renaming now official, the focus turns to translating this recognition into tangible improvements in diagnosis, treatment, and quality of life for those affected.